MediWound announces results from comparison of EscharEx vs SANTYL

MediWound announced the results of head-to-head comparison analyses of EscharEx, the Company’s lead asset in development for chronic wounds, to collagenase SANTYL ointment, approved by the FDA for debriding chronic dermal ulcers. Results from the previously disclosed Phase II study which evaluated the safety and efficacy of EscharEx, demonstrated the superiority of EscahrEx vs. a gel vehicle and non-surgical standard of care, in achieving complete debridement of non-viable tissue and promotion of granulation tissue. Results highlights: The incidence of complete debridement during the daily treatment period was 63.0% for EscharEx vs. 0% for SANTYL. The estimated median time to achieve complete debridement during the study was 9 days for EscharEx vs. not achieved for SANTYL. The incidence of achieving complete debridement and complete cover of the wound bed with granulation tissue during the daily treatment period was 50.0% for EscharEx vs. 0% for SANTYL. The incidence of achieving WBP throughout the study was 78.3% for EscharEx vs. 37.5% for SANTYL. The estimated median time to achieve WBP was 11 days for EscharEx vs. not achieved for SANTYL. 15 of the 46 patients treated with EscharEx completely closed their wounds during the study, compared to 2 out of 8 patients treated with SANTYL. In those patients who achieved complete wound closure, the average time to wound closure was 48.4 days for EscharEx vs. 76.0 days for SANTYL. Patient reported applicational pain was comparable in both groups. The safety profile and overall incidence of adverse wound reactions were comparable between arms.